Previous 10 | Next 10 |
VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ...
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new data that add to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients at risk for major adverse cardiovascular events will b...
HLS Therapeutics (OTCPK:HLTRF) has entered into a promotional services agreement with Pfizer (NYSE:PFE) for the promotion of Vascepa in Canada. Under terms of the Agreement, Pfizer will deploy a team across Canada to support education about Vascepa with primary care physician groups. HLS will...
3 Top Robinhood Penny Stocks For Your August Watchlist We’ve been covering penny stocks on Robinhood heavily over the past year or so. This is the result of the sizable investor interest in them, and the major attention that Robinhood has right now. In addition, Robinhood as ...
Shares of Amarin (NASDAQ: AMRN) are up 9% to $4.84 apiece as of 2:30 p.m. EDT. The company released spectacular second-quarter earnings. Revenue went up 14% year over year to $154.5 million. Simultaneously its net income grew to $6.2 million compared to a loss of $16.1 mil...
Amarin Corporation plc (AMRN) Q2 2021 Earnings Conference Call August 5, 2021 7:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Karim Mikhail - President and Chief Executive Officer Conference Call Participants Ken Cacciatore - Cowen Yasmeen Rahimi - Piper Sandler Louise ...
The following slide deck was published by Amarin Corporation plc in conjunction with their 2021 Q2 earnings call. For further details see: Amarin Corporation plc 2021 Q2 - Results - Earnings Call Presentation
Image source: The Motley Fool. Amarin (NASDAQ: AMRN) Q2 2021 Earnings Call Aug 05, 2021 , 7:30 a.m. ET Operator Continue reading For further details see: Amarin (AMRN) Q2 2021 Earnings Call Transcript
Amarin (NASDAQ:AMRN) reported second-quarter results that beat Wall Street estimates, helped by U.S. sales of VASCEPA, and provided a cash position update. The company's quarterly revenue rose 14% to $154.49M, beating analysts' average estimate by $1.21M. The increase total revenue was driven...
Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany Filed Several Market Access Dossiers in Europe with Proposed Pricing of approximately €200 per Month New CEO, Karim Mikhail, to Host Conference Call Today at 7:30 a.m. ET ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...